{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T05:56:26Z","timestamp":1735883786557,"version":"3.32.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-05931-5","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T03:32:18Z","timestamp":1723260738000},"page":"6035-6037","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A brisk peripheral T-cell reaction following rituximab treatment for follicular lymphoma"],"prefix":"10.1007","volume":"103","author":[{"given":"Cristina","family":"Frusteri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isacco","family":"Ferrarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,10]]},"reference":[{"key":"5931_CR1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/bjh.18881","volume":"202","author":"C Laurent","year":"2023","unstructured":"Laurent C, Flores M, Chartier L, Huet S, Bolen CR, Venstrom JM et al (2023) Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen. Br J Haematol 202:686\u2013689","journal-title":"Br J Haematol"},{"key":"5931_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.humpath.2007.05.026","volume":"39","author":"P Raynaud","year":"2008","unstructured":"Raynaud P, Caulet-Maugendre S, Foussard C, Salles G, Moreau A, Rossi JF et al (2008) T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy? Hum Pathol 39:194\u2013200","journal-title":"Hum Pathol"},{"key":"5931_CR3","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","volume":"113","author":"SP Hilchey","year":"2009","unstructured":"Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F et al (2009) Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a vaccinal effect of Rituximab. Blood 113:3809\u20133812","journal-title":"Blood"},{"key":"5931_CR4","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","volume":"104","author":"G Cartron","year":"2004","unstructured":"Cartron G, Watier H, Golay J, Solal-Celigny P (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104:2635\u20132642","journal-title":"Blood"},{"key":"5931_CR5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"A Freedman","year":"2020","unstructured":"Freedman A, Jacobsen E (2020) Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 95:316\u2013327","journal-title":"Am J Hematol"},{"key":"5931_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.immuni.2018.10.005","volume":"49","author":"M Guilliams","year":"2018","unstructured":"Guilliams M, Mildner A, Yona S (2018) Developmental and Functional Heterogeneity of monocytes. Immunity 49:595\u2013613","journal-title":"Immunity"},{"key":"5931_CR7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2326-6066.CIR-15-0120","volume":"3","author":"DJ DiLillo","year":"2015","unstructured":"DiLillo DJ, Ravetch JV (2015) Fc-Receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. Cancer Immunol Res 3:704\u2013713","journal-title":"Cancer Immunol Res"},{"key":"5931_CR8","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1182\/blood-2009-10-248609","volume":"116","author":"R Ab\u00e8s","year":"2010","unstructured":"Ab\u00e8s R, G\u00e9liz\u00e9 E, Fridman WH, Teillaud JL (2010) Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116:926\u2013934","journal-title":"Blood"},{"key":"5931_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/leu.2014.275","volume":"29","author":"C Deligne","year":"2015","unstructured":"Deligne C, Metidji A, Fridman WH, Teillaud JL (2015) Anti-CD20 therapy induces a memory Th1 response through the IFN-\u03b3\/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia 29:947\u2013957","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05931-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05931-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05931-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:07:10Z","timestamp":1735866430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05931-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5931"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05931-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,8,10]]},"assertion":[{"value":"12 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The participant has consented to the submission of the case report to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}